比较最近批准的用于晚期胆道癌的免疫治疗药物的临床试验结果。
Comparison of Clinical Trial Results of the Recently Approved Immunotherapeutic Drugs for Advanced Biliary Tract Cancers.
机构信息
Department of Public Health, Harvard Medical School, Boston, MA02115, USA.
出版信息
Rev Recent Clin Trials. 2024;19(2):81-90. doi: 10.2174/0115748871276666240123043710.
The recently approved immunotherapeutic drugs are Keytruda (pembrolizumab) and Imfinzi (durvalumab) for advanced biliary tract cancers that inhibit PD-1 receptor and PD-L1 ligand, respectively. In this perspective, the results of the two clinical trials, i.e., TOPAZ-1 (NCT03875235) and KEYNOTE-966 (NCT04003636), are critically appraised, compared, and discussed to assess the benefits of these two drugs in the context of the treatment of advanced biliary tract cancers with a focus on PD-L1 status and MIS (microsatellite instability) status and therapy responsiveness in the subgroups. Analyzing the PD-L2 status in biliary tract cancer patients can aid in assessing the prognostic value of PD-L2 expression in determining the clinical response and this may aid in appropriate patient stratification.
最近批准的免疫治疗药物分别是 Keytruda（pembrolizumab）和 Imfinzi（durvalumab），用于治疗抑制 PD-1 受体和 PD-L1 配体的晚期胆道癌。从这个角度来看，对两项临床试验，即 TOPAZ-1（NCT03875235）和 KEYNOTE-966（NCT04003636）的结果进行了批判性评估、比较和讨论，以评估这两种药物在治疗晚期胆道癌方面的益处，重点关注 PD-L1 状态和 MIS（微卫星不稳定性）状态以及亚组中的治疗反应性。分析胆道癌患者的 PD-L2 状态有助于评估 PD-L2 表达在确定临床反应方面的预后价值，这可能有助于对患者进行适当的分层。
Zotero 插件